Objective To evaluate the effect of Xiaoji Beverage（消积饮） as a maintenance treatment on quality of life in stage ⅢB/Ⅳ non-small cell lung cancer（NSCLC） patients with epidermal growth factor receptor（EGFR） wild-type. Methods Seventy-four NSCLC patients with EGFR wild-type were randomly divided into three groups

with 23 patients in the traditional Chinese medicine（TCM） group

24 patients in the western medicine（WM） group

and 27 patients in the combination group. Xiaoji Beverage was orally administered in TCM group

one dose daily

for 21 days as a course. Tiggio capsules were orally taken in WM group

with dosage calculated based on body surface area

twice daily for 14 days

and a medication stop for 7 days

totally 21 days as a course. The combination group provided Xiaoji Beverage plus tiggio capsules

and the administration ways were the same as the other two groups. Patients received treatment until the cancer had progressed

or side effects became intolerable

or patients had died. The first quartile（25%）

median（50%）

and third quartile（75%） progression free survival（PFS） time were calculated

as well as the 3-month and 6-month PFS rates. Lung cancer symptom scale（LCSS） was used to evaluate the quality of life before and after treatment[（42±3）days]. Results There were no statistically significant differences among three groups in PFS time（P=0.34）. The 3-month PFS rate of WM group

TCM group and combination group were 29.17%

21.74% and 29.63% respectively（P=0.789）

and the 6-month PFS rate of three groups were 8.33%

17.39%

and 25.93% respectively（P=0.257）; the comparison among three groups in 3-month PFS rate and 6-month PFS rate were not statistically significant. The LCSS scores significantly increased after treatment compared to before treatment in WM group（P=0.038） and in combination group（P=0.046）

while there was no difference in TCM group（P=0.195）. After treatment

the LCSS score of TCM group was significantly lower than that of WM group（P=0.005）. Conclusion Xiaoji Beverage

as a maintenance treatment for stage ⅢB/Ⅳ NSCLC patients with EGFR wild-type

can prolong the progression free survival time

and is better than tiggio capsules in improving the quality of life.